BRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), and Air Lease Corporation (NYSE - AL)
Investigations Announced: Brodsky & Smith is reminding investors of ongoing investigations into several companies regarding potential breaches of fiduciary duties by their boards during acquisition processes.
Akero Therapeutics Acquisition: Akero Therapeutics is set to be acquired by Novo Nordisk for $54.00 per share, with additional contingent payments tied to regulatory approval of a treatment, raising concerns about the fairness of the deal for shareholders.
CoreCard Corporation Merger: CoreCard Corporation will merge with Euronet in a stock-for-stock transaction valued at approximately $248 million, prompting investigations into whether the board acted in the best interest of shareholders.
Air Lease and PB Bankshares Transactions: Air Lease will be acquired for $65.00 per share, while PB Bankshares will be merged with Norwood Financial, with both transactions under scrutiny for potential fiduciary duty breaches by their respective boards.
Trade with 70% Backtested Accuracy
Analyst Views on AL
About AL
About the author


- Acquisition Announcement: Sumitomo Corporation, along with SMBC Aviation Capital, Apollo, and Brookfield, has completed the acquisition of Air Lease Corporation.
- Strategic Move: This acquisition is part of a strategic initiative to enhance their presence in the aviation sector.
- Index Component Change: Atmus Filtration Technologies will replace Air Lease in the S&P SmallCap 600 Index before the market opens on April 9, reflecting market recognition of Atmus and potentially enhancing its liquidity and investor interest.
- Acquisition Impact: Air Lease is being acquired by a consortium led by Sumitomo, with the transaction expected to close soon, which will remove Air Lease from the small-cap index and may affect its stock performance and market positioning.
- Sector Classification Consistency: Both Atmus and Air Lease are classified under the Industrials sector, and this component change helps maintain the industry representation of the S&P SmallCap 600 Index, ensuring investors can better reflect the overall performance of the sector.
- Future Growth Expectations: Atmus projects a revenue growth of 10%-14% in 2026, driven by the Koch acquisition and the launch of new business segments, which will further enhance its performance and investment appeal within the small-cap index.
- Index Change: Atmus Filtration Technologies Inc. will replace Air Lease Corp. in the S&P SmallCap 600 effective April 9, 2026, marking a significant elevation in the company's status within the small-cap market, potentially attracting more investor attention.
- Acquisition Update: Sumitomo Corporation and Consortium are acquiring Air Lease Corp., with the deal expected to close soon, which may impact Air Lease's market performance and shareholder interests.
- Sector Impact: This change occurs within the industrial sector, and Atmus's inclusion could enhance the overall performance of the index, reflecting increased market confidence in industrial companies.
- Investor Focus: With Atmus's addition, investors may reassess their portfolios, particularly in the small-cap space, further driving liquidity and market recognition for the company’s stock.
- Index Change: Atmus Filtration Technologies Inc. will replace Air Lease Corp. in the S&P SmallCap 600 effective April 9, 2026, indicating a significant recognition of the company in the small-cap market, which is likely to attract more investor attention.
- Acquisition Dynamics: Sumitomo Corporation and Consortium are acquiring Air Lease Corp., with the deal expected to close soon, potentially impacting Air Lease's market performance and investor confidence.
- Industry Impact: The addition of Atmus Filtration is set to enhance the industrial sector's performance within the S&P SmallCap 600 index, which may increase the overall attractiveness of the index and draw in more capital.
- Market Reaction: With Atmus Filtration's inclusion, market expectations regarding its future growth potential could drive its stock price up, thereby strengthening its position among investors.
- Market Performance: Major Wall Street indices closed mostly lower on Monday, with the tech-heavy Nasdaq Composite down 0.7%, the S&P 500 declining by 0.3%, while the Dow Jones managed a slight gain of 0.1%, reflecting investor caution amid ongoing Middle East conflict during the holiday-shortened trading week.
- Viridian Therapeutics Under Pressure: Viridian Therapeutics (VRDN) faced significant pressure in premarket trading after a 32% drop following the release of topline results from its Phase 3 REVEAL-1 trial, which, despite meeting its primary endpoint, left investors underwhelmed due to a 54% proptosis responder rate compared to 18% for placebo, indicating concerns over overall efficacy.
- Boston Scientific Cautious Trading: Boston Scientific (BSX) traded cautiously in premarket activity after a 9% decline on Monday, even though its CHAMPION-AF study for the Watchman FLX device met primary and secondary endpoints; however, investors noted a slightly higher ischemic stroke rate of 3.2% compared to 2% for blood thinners, raising concerns about the device's safety profile.
- M&T Bank Share Buyback: M&T Bank (MTB) saw its stock rise in premarket trading after announcing a new $5 billion share repurchase program, replacing a previous $4 billion plan approved in January 2025, which underscores the company's commitment to enhancing shareholder value while maintaining discretion over the timing and terms of repurchases.









